165 related articles for article (PubMed ID: 29099466)
1. Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function.
Austin GL; Weiskopf JR; Czwornog JL
J Clin Gastroenterol; 2018 Sep; 52(8):691-695. PubMed ID: 29099466
[TBL] [Abstract][Full Text] [Related]
2. Healthy Lifestyle Characteristics and Their Joint Association With Cardiovascular Disease Biomarkers in US Adults.
Loprinzi PD; Branscum A; Hanks J; Smit E
Mayo Clin Proc; 2016 Apr; 91(4):432-42. PubMed ID: 26906650
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
4. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population.
Devraj R; Deshpande M
Res Social Adm Pharm; 2020 Jun; 16(6):776-782. PubMed ID: 31445985
[TBL] [Abstract][Full Text] [Related]
5. No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.
Kruszelnicka O; Kuźma M; Pena IZ; Perera IB; Chyrchel B; Wieczorek-Surdacka E; Surdacki A
Int J Med Sci; 2017; 14(10):1015-1021. PubMed ID: 28924374
[No Abstract] [Full Text] [Related]
6. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.
Fortuna LA; Pawloski PA; Parker ED; Trower NK; Kottke TE
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):13-9. PubMed ID: 27533057
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use.
Chowdhry M; Shah K; Kemper S; Zekan D; Carter W; McJunkin B
J Gastroenterol Hepatol; 2018 Oct; 33(10):1717-1721. PubMed ID: 29514412
[TBL] [Abstract][Full Text] [Related]
9. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?
Mikolasevic I; Milic S; Stimac D; Zaputovic L; Lukenda Zanko V; Gulin T; Jakopcic I; Klaric D; Gulin M; Orlic L
Eur J Intern Med; 2016 May; 30():99-103. PubMed ID: 26905320
[TBL] [Abstract][Full Text] [Related]
10. The association of proton pump inhibitors and chronic kidney disease: cause or confounding?
Li T; Xie Y; Al-Aly Z
Curr Opin Nephrol Hypertens; 2018 May; 27(3):182-187. PubMed ID: 29432214
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study.
Rooney MR; Bell EJ; Alonso A; Pankow JS; Demmer RT; Rudser KD; Chen LY; Lutsey PL
J Clin Gastroenterol; 2021 Sep; 55(8):677-683. PubMed ID: 33471493
[TBL] [Abstract][Full Text] [Related]
12. Association of proton pump inhibitor use with risk of kidney stones: an analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2007-2018).
Liu W; Wang J; Wang M; Wang M; Liu M
BMJ Open; 2023 Oct; 13(10):e075136. PubMed ID: 37844987
[TBL] [Abstract][Full Text] [Related]
13. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients.
Shikata T; Sasaki N; Ueda M; Kimura T; Itohara K; Sugahara M; Fukui M; Manabe E; Masuyama T; Tsujino T
Circ J; 2015; 79(1):193-200. PubMed ID: 25392070
[TBL] [Abstract][Full Text] [Related]
14. Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain.
Czwornog JL; Austin GL
Nutrients; 2015 Oct; 7(10):8592-601. PubMed ID: 26492268
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK.
Cooksey R; Kennedy J; Dennis MS; Escott-Price V; Lyons RA; Seaborne M; Brophy S
PLoS One; 2020; 15(9):e0237676. PubMed ID: 32946449
[TBL] [Abstract][Full Text] [Related]
16. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
[TBL] [Abstract][Full Text] [Related]
17. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
18. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.
Misra PS; Alam A; Lipman ML; Nessim SJ
BMC Nephrol; 2015 Aug; 16():136. PubMed ID: 26268579
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiometabolic risk biomarkers from a national clinical laboratory with the US adult population.
Wolin E; White J; Pottala JV; Sasinowski M; Dall T; Dayspring TD; McConnell JP; Hoefner DM; Varvel SA; Thiselton DL; Warnick GR; Harris WS
J Clin Lipidol; 2015; 9(6):817-823. PubMed ID: 26687703
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011-2012 National Health and Nutrition Examination Survey.
Deng C; Zhang Z; Li H; Bai P; Cao X; Dobs AS
Aging Male; 2019 Jun; 22(2):121-128. PubMed ID: 29925274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
